title: The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.
abstract: Studies into the mechanisms in resolution of self-limited inflammation and acute reperfusion injury have uncovered a new genus of pro-resolving lipid mediators coined specialized pro-resolving mediators (SPM) including lipoxins, resolvins, protectins and maresins that are each temporally produced by resolving-exudates with distinct actions for return to homeostasis. SPM evoke potent anti-inflammatory and novel pro-resolving mechanisms as well as enhance microbial clearance. While born in inflammation-resolution, SPM are conserved structures with functions discovered in microbial defense, pain, organ protection and tissue regeneration, wound healing, cancer, reproduction, and neurobiology-cognition. This review covers these SPM mechanisms and other new omega-3 PUFA pathways that open their path for functions in resolution physiology.
authors: Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States. Electronic address: cnserhan@zeus.bwh.harvard.edu.
authors: Charles N
authors: CN
authors: Serhan
authors: Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
authors: Nan
authors: N
authors: Chiang
authors: Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
authors: Jesmond
authors: J
authors: Dalli
mesh_terms: D000208:Acute Disease; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004281:Docosahexaenoic Acids / Q000378:metabolism; D005228:Fatty Acids, Essential / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000378:metabolism*; D006706:Homeostasis / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology*; D018836:Inflammation Mediators / Q000276:immunology*; D050356:Lipid Metabolism / Q000276:immunology*; D044045:Lipoxins / Q000378:metabolism; D051379:Mice; D015427:Reperfusion Injury / Q000276:immunology / Q000473:pathology; D014945:Wound Healing / Q000502:physiology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005228:Fatty Acids, Essential; D015525:Fatty Acids, Omega-3; D018836:Inflammation Mediators; D044045:Lipoxins; D004281:Docosahexaenoic Acids; D001241:Aspirin
keywords: Essential fatty acids; Host defense; Infection; Inflammation; Lipid mediator